The FDA approved an obesity drug despite concerns that it might increase the risk of heart valve problems. This release is in response to more than 1/3 of Americans are considered obese (a BMI of at least 30). This drug, lorcaserin hydrochloride (Belviq) is a scheduled drug meaning no more than a 30 day prescription. Patients taking lorcaserin for up to a year had an average weight loss of 3.7%. This drug is not allowed during pregnancy. Side effects may include problems with thinking, confusion, sleepiness, and in higher doses, hallucinations, euphoria or dissociation.
Consider weight loss and exercise. Side effects and risks are better.